Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jan;61(1):51–55. doi: 10.1038/bjc.1990.11

Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia.

W L Skinner 1, D Murray 1, V Kohli 1, M Beran 1, K B McCredie 1, E J Freireich 1, B S Andersson 1
PMCID: PMC1971335  PMID: 2297490

Abstract

Sublines of a human myeloid leukaemia cell line, KBM-3, with increasing degrees of resistance to the antileukaemic agent 4'-(9-acridinlylamino) methanesulphon-m-anisidide (m-AMSA) were evaluated for their response to this drug using a clonogenic assay to measure cell survival and alkaline elution to assess m-AMSA induced DNA strand breakage. Polyacrylamide gel electrophoresis was used to map the protein profiles of the various cell lines. The resistant lines were obtained by intermittent exposure of the KBM-3 cells to the highest tolerated concentration of m-AMSA so that the culture would be repopulated only by the most resistant subpopulation after each exposure. Two distinct phases were apparent during the development of resistance. During the first 14 months of intermittent exposure to maximally tolerated concentrations of m-AMSA, the cells developed low-degree m-AMSA resistance (5-7-fold as compared with the parent line, as measured by cell survival). This low-degree resistance was characterised by a somewhat suppressed level of DNA strand breakage and no measurable change in cellular protein levels. Subsequently, a single escalation of the m-AMSA retreatment concentration resulted in a cell population that was approximately 100-fold resistant, as assessed by cloning. This rapid phenotypic change temporally coincided with the acquisition of an almost complete refractoriness to m-AMSA-induced DNA strand breakage and the loss of a cellular 76 kDa protein. We suggest that the loss of this protein is important for the development of a highly m-AMSA resistant phenotype.

Full text

PDF
51

Images in this article

54Figure 5
on p.54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakic M., Beran M., Andersson B. S., Silberman L., Estey E., Zwelling L. A. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA). Biochem Biophys Res Commun. 1986 Jan 29;134(2):638–645. doi: 10.1016/s0006-291x(86)80467-3. [DOI] [PubMed] [Google Scholar]
  2. Beran M., Andersson B. S. Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. Cancer Res. 1987 Apr 1;47(7):1897–1904. [PubMed] [Google Scholar]
  3. Collins S. J., Gallo R. C., Gallagher R. E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977 Nov 24;270(5635):347–349. doi: 10.1038/270347a0. [DOI] [PubMed] [Google Scholar]
  4. Estey E. H., Silberman L., Beran M., Andersson B. S., Zwelling L. A. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun. 1987 Apr 29;144(2):787–793. doi: 10.1016/s0006-291x(87)80033-5. [DOI] [PubMed] [Google Scholar]
  5. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., Metzgar R., Aulakh G., Ting R., Ruscetti F. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979 Sep;54(3):713–733. [PubMed] [Google Scholar]
  6. Keating M. J., Gehan E. A., Smith T. L., Estey E. H., Walters R. S., Kantarjian H. M., McCredie K. B., Freireich E. J. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol. 1987 May;5(5):710–721. doi: 10.1200/JCO.1987.5.5.710. [DOI] [PubMed] [Google Scholar]
  7. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  8. Legha S. S., Keating M. J., McCredie K. B., Bodey G. P., Freireich E. J. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood. 1982 Aug;60(2):484–490. [PubMed] [Google Scholar]
  9. Legha S. S., Keating M. J., Zander A. R., McCredie K. B., Bodey G. P., Freireich E. J. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med. 1980 Jul;93(1):17–21. doi: 10.7326/0003-4819-93-1-17. [DOI] [PubMed] [Google Scholar]
  10. O'Farrell P. H., O'Farrell P. Z. Two-dimensional polyacrylamide gel electrophoretic fractionation. Methods Cell Biol. 1977;16:407–420. doi: 10.1016/s0091-679x(08)60116-8. [DOI] [PubMed] [Google Scholar]
  11. Odaimi M., Andersson B. S., McCredie K. B., Beran M. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 1986 Jul;46(7):3330–3333. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES